Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 49: EUROPA-Studie - Klinische Aussagen Abb. 50: EUROPA-Studie - KHK Abb. 51: EUROPA-Studie - KHK Aktuelles Bild - Abb. 52: EUROPA-Studie - Perindopril - Benefit Abb. 53: EUROPA-Studie - Interaktionsanalyse Abb. 54: EUROPA-Studie - Benefits Abb. 55: EUROPA-Studie - HOPE-Studie Zum letzten Bild
Abbildung 52: EUROPA-Studie - Perindopril - Benefit
In EUROPA study, all at-risk patients benefited, whether they were in low, medium or high risk group of patients. Perindopril 8 mg once daily reduced primary end-point (CV death, MI or cardiac arrest) regardless of age, gender, previous history of coronary artery disease (MI, CABG/PTCA, PVD, stroke), risk factors (smoking, diabetes) or preventive therapy (platelet inhibitors, lipid lowering drugs or B-blockers).
 
EUROPA-Studie - Perindopril - Benefit
Vorheriges Bild Nächstes Bild   


Abbildung 52: EUROPA-Studie - Perindopril - Benefit
In EUROPA study, all at-risk patients benefited, whether they were in low, medium or high risk group of patients. Perindopril 8 mg once daily reduced primary end-point (CV death, MI or cardiac arrest) regardless of age, gender, previous history of coronary artery disease (MI, CABG/PTCA, PVD, stroke), risk factors (smoking, diabetes) or preventive therapy (platelet inhibitors, lipid lowering drugs or B-blockers).
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung